5542-92-7 Usage
General Description
The chemical 5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol, also known as cladribine, is a synthetic purine nucleoside analog with immunosuppressive and antineoplastic properties. It is used in the treatment of hairy cell leukemia, multiple sclerosis, and some autoimmune diseases. Cladribine interferes with DNA synthesis and repair, leading to the disruption of cellular processes and ultimately causing cell death. It is administered either orally or as a subcutaneous injection and has been shown to be effective in reducing disease activity and controlling symptoms in patients with these conditions. However, it also carries the risk of adverse effects and requires careful monitoring during treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 5542-92-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,5,4 and 2 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5542-92:
(6*5)+(5*5)+(4*4)+(3*2)+(2*9)+(1*2)=97
97 % 10 = 7
So 5542-92-7 is a valid CAS Registry Number.
5542-92-7Relevant articles and documents
Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods
-
Paragraph 0151, (2016/04/06)
A process of regiospecific synthesis of N-9 purine nucleoside analogs in either solution or solid phase synthesis is described. The introduction of the sugar moiety or its analogue on to a 6-heteroarylium purine or its mesomeric betaine so that formation of only the N-9 position regioisomers of the purine nucleoside analogs (either D or L enantiomers) is obtained. This regiospecific introduction of the sugar moiety allows the synthesis of purine nucleoside analogs in high yields without formation of the N-7-positional regioisomers, while the 6-heteroaryliums are leaving groups facilitated for nucleophilic displacement. Solid supported 6-heterarylium purine bases can be used for purine based library synthesis and synthesis of nucleotide monophosphates and polyphosphates. Processes for providing novel 6-heteroarylium purines and their corresponding mesomeric betaines for the regiospecific synthesis of N-9 purine nucleoside analogs and nucleotides are described.
